Sumary of Hydrogel capsule for weight loss may reduce risk for liver fibrosis:
- Plenity treatment in the Gelesis Loss of Weight (GLOW) study is associated with improvement in liver health, as measured by NAFLD fibrosis score..
- Still reports he has received consultant and speaker fees from Covidien, Ethicon Endo-Surgery and Novo Nordisk, and has received research grants from Ethicon Endo-Surgery..
- An oral hydrogel capsule for treatment of obesity may reduce liver fibrosis risk, according to an exploratory analysis of the GLOW study presented at the American Association of Clinical Endocrinology annual meeting..
- “We know that patients with excess weight are at increased risk for developing nonalcoholic fatty liver disease, or NAFLD,”.
- Christopher Still, DO, FACP, medical director for the Center for Nutrition and Weight Management and director of the Geisinger Obesity Research Institute at Geisinger Medical Center, told Healio..
- “This chronic disease is a silent disease because its early development is generally asymptomatic but can progress to nonalcoholic steatohepatitis, liver fibrosis, cirrhosis and liver cancer..
- The first-line treatment for NAFLD is weight loss, and we know that around 7% weight loss can result in improved liver enzymes and less liver inflammation..
- Since we collected all of the clinical values that are used to calculate the NAFLD fibrosis score as part of GLOW, it was a natural question to ask whether [hydrogel therapy] could impact participants’ NAFLD fibrosis score.”…